Utah is currently home to 1209 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
NCT06395285
Recruiting
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/19/2025
Locations: John A. Moran Eye Center - University of Utah Health, Salt Lake City, Utah
Conditions: ROSAH
Register for Updates
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates
A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
NCT06887972
Recruiting
The purpose of this study to evaluate the effectiveness, safety, and tolerability of SUZ as part of multimodal therapy (MMT) in treating acute postoperative pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: JBR Clinical Research, Salt Lake City, Utah
Conditions: Acute Pain
Register for Updates
EFS of the DUO System for Tricuspid Regurgitation
NCT05913908
Recruiting
The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Intermountain Health, Salt Lake City, Utah
Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
Register for Updates
Muscle Blood Flow Regulation in HFpEF
NCT05115890
Recruiting
Heart failure with preserved ejection (HFpEF) disproportionately affects Veterans and is the number one reason for hospital discharge in the VA Health Care System. Exercise intolerance is a common complication experienced by patients with HFpEF, perpetuating physical inactivity and accelerating disease progression. This research proposal aims to elucidate mechanisms responsible for inadequate skeletal muscle blood flow and exercise intolerance in patients with HFpEF compared with healthy control... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
Conditions: HFpEF
Register for Updates
Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse
NCT04351113
Recruiting
Prolonged periods of reduced activity are associated with decreased vascular function and muscle atrophy. Physical inactivity due to acute hospitalization is also associated with impaired recovery, hospital readmission, and increased mortality. Older adults are a particularly vulnerable population as functional (vascular and skeletal muscle mitochondrial dysfunction) and structural deficits (loss in muscle mass leading to a reduction in strength) are a consequence of the aging process. The combi... Read More
Gender:
ALL
Ages:
Between 65 years and 85 years
Trial Updated:
04/17/2025
Locations: VA Medical Center, Salt Lake City, Utah
Conditions: Aging, Oxidative Stress, Vascular Endothelium, Skeletal Muscle, Antioxidants
Register for Updates
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
NCT03458832
Recruiting
The primary cause of facioscapulohumeral muscular dystrophy (FSHD), a common adult-onset dystrophy, was recently discovered identifying targets for therapy. As multiple drug companies pursue treatments for FSHD, there is an urgent need to define the clinical trial strategies which will hasten drug development, including creating disease-relevant outcome measures and optimizing inclusion criteria. This proposal will develop two new outcome measures (FSHD-COM and EIM) and optimize eligibility crit... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Facioscapulohumeral Muscular Dystrophy
Register for Updates
The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
NCT06665945
Recruiting
The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears to accurately classify ovarian cancer with relatively high sensitivity and specificity. The SENTRY Study will build upon these retrospective analyses to prospectively recruit women with ovarian cancer o... Read More
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/16/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Ovarian Cancer
Register for Updates
Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool
NCT05706311
Recruiting
This goal of this observational study is to develop and test the Opioid Risk Reduction Clinical Decision Support (ORRCDS) tool. The tool will be an opioid medication risk screener and decision support platform that will be used by pharmacists upon dispensing prescription opioid medication. Once the Opioid Risk Reduction has been developed, we will examine the impact of the ORRCDS within two divisions of a large chain retail pharmacy. Pharmacies will be randomized to using the Opioid Risk Reducti... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/16/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Opioid Abuse, Prescription Opioid Abuse
Register for Updates
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
NCT05535166
Recruiting
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Gender:
ALL
Ages:
59 months and below
Trial Updated:
04/16/2025
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Medulloblastoma
Register for Updates
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT04315233
Recruiting
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients diagnosed with triple-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Register for Updates
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
NCT04523727
Recruiting
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 6 years and 16 years
Trial Updated:
04/15/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Hyperphosphatemia Related to Chronic Kidney Disease
Register for Updates